Skip to main content
Premium Trial:

Request an Annual Quote

Veritas Bio Gets European Patent on Delivery Technology

Premium

Veritas Bio said this week that the European Patent Office has granted the company a patent covering its nucleic acid-delivery technology.

The patent, granted on patent application No. 07873598.21401, is entitled "In Vivo Delivery of Nucleic Acids," and covers the transfection of nucleic acids into skin or muscle cells. A US patent application on the technology was recently issued a notice of allowance.

As reported by Gene Silencing News, Vertias was established by the co-founders of defunct expressed RNAi drug firm Nucleonics as a holding company for the delivery technology while they look for parties interested in licensing the intellectual property (GSN 4/18/2013).

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.